Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the S&P500 top gainers and losers.
Medical technology company Becton, Dickinson and Company (NYSE:BDX) met Wall Streets revenue expectations in Q3 CY2025, with sales up 8.3% year on year to $5.89 billion. Its non-GAAP profit of $3.96 per share was 1.2% above analysts’ consensus estimates.
Medical technology company Becton, Dickinson and Company (NYSE:BDX)
will be reporting results this Thursday before market hours. Here’s what to expect.
Over the past six months, BD’s stock price fell to $181.01. Shareholders have lost 12.6% of their capital, which is disappointing considering the S&P 500 has climbed by 23.8%. This may have investors wondering how to approach the situation.
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
In a groundbreaking advancement that promises to redefine the capabilities of autonomous systems, engineers at the University of Virginia have unveiled HydroSpread, an innovative fabrication method for creating ultrathin soft robots capable of navigating aquatic environments with unprecedented agility. This breakthrough, poised to revolutionize fields from environmental monitoring to search and rescue, marks a significant [...]
The U.S. Commerce Department, under the Trump administration, has launched a national security review of medical imports—including PPE, consumables, and medical devices—to assess reliance on foreign suppliers for critical health products.
Shares of medical technology company Becton, Dickinson and Company (NYSE:BDX)
fell 4.2% in the morning session after RBC Capital initiated coverage on the company with a neutral 'Sector Perform' rating.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
4 analysts have expressed a variety of opinions on Becton Dickinson (NYSE: BDX) over the past quarter, offering a diverse set of opinions from bullish to bearish.
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence.
With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.
Wall Street’s bearish price targets for the stocks in this article signal serious concerns.
Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns.
Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
Let’s dig into the relative performance of BD (NYSE:BDX) and its peers as we unravel the now-completed Q2 surgical equipment & consumables - diversified earnings season.
Medical technology company Becton, Dickinson and Company (NYSE:BDX) met Wall Street’s revenue expectations in Q2 CY2025, with sales up 8.9% year on year to $5.51 billion. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $21.85 billion at the midpoint. Its non-GAAP profit of $3.68 per share was 8.2% above analysts’ consensus estimates.
